Buffalo, NY – Athenex, Inc. announced today the promotion of Jeffrey M. Yordon to the position of Chief Operating Officer (COO) for the company effective upon Board approval. Previously Mr. Yordon was the President of the Athenex Pharmaceutical Division (APD), which was focused on commercializing all of Athenex’s products and intellectual property.
Mr. Yordon has had a long, distinguished career in the pharmaceutical industry with over 47 years of experience. Previous to joining Athenex, he was the Founder, Chairman of the Board and CEO of Sagent Pharmaceuticals which was recently sold to Nichi-Iko Pharmaceutical Company. Mr. Yordon was one of the founders of American Pharmaceutical Partners and served as President and COO of the company which was eventually purchased by Fresenius Kobi. Mr. Yordon also previously held senior management positions at YorPharm, LyphoMed, Faulding Pharmaceuticals and Gensia Laboratories. “I am looking forward to working with the Athenex management team with a view to achieving key milestones and executing on our growth plan,” stated Mr. Yordon.